Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

By sjmartinez • April 27, 2023

Hendershot A, Slabaugh M, Riaz KM, Moore KN, O'Malley DM, Matulonis U, Konecny GE. Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. Gynecol Oncol Rep. 2023 Feb 28;47:101155. doi: 10.1016/j.gore.2023.101155. PMID: 37102083; PMCID: PMC10123335.

Tags: Antibody-drug conjugates, Eye care, Folate receptor alpha, Hematology/Oncology, Mirvetuximab soravtansine, Ocular adverse events, ovarian cancer, Publications

Related Posts

US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan

Rugo H, Bardia A, Bruno DS, Ernani V, Hamilton E, Heist R, Jhaveri K, Levy B, Lisberg A, O'Shaughnessy J, Sands J, Spira A, Tolaney[...]

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial

Melisi D, Macarulla T, De La Fouchardière C, Pazo Cid RA, Chandana SR, Kiss I, Lee WJ, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab[...]

Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study

Milhem MM, Zakharia Y, Davar D, Buchbinder EI, Medina T, Daud A, Ribas A, Chmielowski B, Niu J, Gibney GT, Margolin K, Olszanski AJ, Mehmi[...]